Skip to main content
Frontiers in Endocrinology logoLink to Frontiers in Endocrinology
. 2023 Mar 2;14:1158214. doi: 10.3389/fendo.2023.1158214

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Martin Bidlingmaier 1,*, Beverly MK Biller 2, David Clemmons 3, Jens Otto L Jørgensen 4, Hiroshi Nishioka 5, Yutaka Takahashi 6,7
PMCID: PMC10022694  PMID: 36936137

Incorrect copyright statement

In the published article, there was an error in the Copyright statement of Figure 1 . The statement was incorrectly written as “Reproduced with permission (24).”. The corrected statement is “Reproduced from Bentz Damholt et al. (24) under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/). No changes were made to this figure.”

Figure 1.

Figure 1

Simulated weekly IGF-I SDS levels following dosing with somapacitan (weekly GH [mean dose 2.4 mg]) and somatropin (daily GH [mean dose 0.3 mg]). Dashed line is weekly average IGF-I SDS for somapacitan (-0.09 SDS). Reproduced from Bentz Damholt et al. (24) under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Endocrinology are provided here courtesy of Frontiers Media SA

RESOURCES